Johnson & Johnson's stock surged 1.43% on Nov 6, 2026, with $2.43B turnover, driven by FDA approval of RYBREVANT FASPRO for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results